Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second intraperitoneal catumaxomab cycle in malignant ascites after CASIMAS
2009-014076-22Phase 2Completed
- Sponsor
- Fresenius
- Start
- Aug 2009
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in malignant ascites and carcinoma, sponsored by Fresenius. Primary endpoint: Proportion able to receive second cycle. Started Aug 2009; status: completed.
02
Drugs
catumaxomab
03
Conditions
malignant ascitescarcinoma
Beyond the preview
Go deeper on 2009-014076-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014076-22.